Genscript Biotech (HKSE:01548) 3-Year Book Growth Rate : 6.10% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech 3-Year Book Growth Rate?

Genscript Biotech's Book Value per Share for the quarter that ended in Dec. 2023 was HK$5.12.

During the past 12 months, Genscript Biotech's average Book Value per Share Growth Rate was 37.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was 6.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was 22.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 10 years, the highest 3-Year average Book Value per Share Growth Rate of Genscript Biotech was 63.50% per year. The lowest was 6.10% per year. And the median was 32.80% per year.

Competitive Comparison of Genscript Biotech's 3-Year Book Growth Rate

For the Biotechnology subindustry, Genscript Biotech's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genscript Biotech's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's 3-Year Book Growth Rate falls into.

Genscript Biotech 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Genscript Biotech (HKSE:01548) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Genscript Biotech 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Genscript Biotech (HKSE:01548) Headlines

No Headlines